The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC).
Ramesh Omranipour, Bita Eslami, Sadaf Alipour et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the impact of locoregional treatment (LRT) on overall survival (OS) in 250 patients with non-progressive de novo metastatic breast cancer (DnMBC) undergoing systemic treatment. The study found no significant OS difference between the LRT group (n=158) and the systemic treatment (ST) group (n=92), with a 5-year OS of 43% overall. The median time to death was 53 months for LRT and 55 months for ST.
Key findings
- The 2-year OS was 81% and the 5-year OS was 43% for the entire cohort.
- Median time to death was 53 months in the LRT group and 55 months in the ST group.
- No OS differences were found between LRT and ST groups (p = 0.6).
- Patients with HER2+ and lung metastasis had a higher risk of death.
Why it matters
Understanding the role of locoregional treatment in DnMBC is crucial for optimizing patient management. This study suggests that LRT may not confer additional survival benefits, highlighting the need for careful consideration of treatment strategies in this population.